GlassScriptPhysician profile
Sarah E Lemoine
NPI 1669028429
$3,578.46
in general payments reported to CMS, 2019-2025
20 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $437 · 2023: $644 · 2024: $998 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,755.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $461.90 | 2021-2025 | Epclusa |
| Renalytix Ai, INC. | $436.43 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $433.07 | 2022-2024 | Mounjaro, Olumiant |
| Abbvie INC. | $376.41 | 2021-2025 | |
| Amgen INC. | $325.12 | 2025 | Repatha, Krystexxa, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $253.84 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.35 | 2024-2025 | Caplyta |
| Genzyme Corporation | $155.73 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $122.02 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $119.52 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $117.31 | 2025 | Dupixent |
| Axsome Therapeutics, INC. | $111.92 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $96.99 | 2022-2023 | Quviviq |
| Cardiovascular Systems INC. | $96.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $91.31 | 2024 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $78.80 | 2022 | |
| Exact Sciences Corporation | $22.13 | 2025 | The Cologuard Plus Collection Kit |
| Azurity Pharmaceuticals, INC. | $15.13 | 2023 | Adthyza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lemoine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.